{"product_id":"management-strategies-in-antithrombotic-therapy-9780470319383","title":"Management Strategies in Antithrombotic Therapy","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eIntravascular thrombus formation remains one of the most significant problems in cardiovascular medicine. It underlies the clinical presentation of acute coronary syndromes, including unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\"This book is an invaluable resource for all postgraduate students and specialist physicians in cardiovascular medicine, cardiac and vascular surgery, and critical care.\" (\u003ci\u003eDoody's\u003c\/i\u003e, April 2008)\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cb\u003eAbbreviations and Acronyms.\u003c\/b\u003e  \u003cp\u003e\u003cb\u003ePreface.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 1. \u003cb\u003eThrombosis and Antithrombotics in Vascular Disease.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1.1 The Burden of Thrombosis.\u003c\/p\u003e \u003cp\u003e1.2 Essential components of thrombosis.\u003c\/p\u003e \u003cp\u003e1.3 Thrombosis in the acute ischemic syndromes.\u003c\/p\u003e \u003cp\u003e1.4 Venous thromboembolic disease.\u003c\/p\u003e \u003cp\u003e1.5 The ideal antithrombotic agent.\u003c\/p\u003e \u003cp\u003eChapter 2. \u003cb\u003eAspirin.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction.\u003c\/p\u003e \u003cp\u003e2.2 Pharmacology.\u003c\/p\u003e \u003cp\u003e2.3 Clinical uses of aspirin.\u003c\/p\u003e \u003cp\u003e2.4 Conclusions.\u003c\/p\u003e \u003cp\u003eChapter 3. \u003cb\u003eThienopyridines – Ticlopidine and Clopidogrel.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction.\u003c\/p\u003e \u003cp\u003e3.2 Pharmacology.\u003c\/p\u003e \u003cp\u003e3.3 Clinical uses of the thienopyridines.\u003c\/p\u003e \u003cp\u003e3.4 Conclusions.\u003c\/p\u003e \u003cp\u003eChapter 4. \u003cb\u003ePlatelet Glycoprotein IIb\/IIIa Inhibitors.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction.\u003c\/p\u003e \u003cp\u003e4.2 GP IIb\/IIIa receptor inhibitors.\u003c\/p\u003e \u003cp\u003e4.3 GP IIb\/IIIa inhibitors during percutaneous coronary revascularization.\u003c\/p\u003e \u003cp\u003e4.4 GP IIb\/IIIa inhibitors in the management of non-st-elevation ACS.\u003c\/p\u003e \u003cp\u003e4.5 GP IIb\/IIIa inhibitors in the management of acute STEMI.\u003c\/p\u003e \u003cp\u003e4.6 Safety of GP IIb\/IIIa inhibitors.\u003c\/p\u003e \u003cp\u003e4.7 Summary.\u003c\/p\u003e \u003cp\u003eChapter 5. \u003cb\u003eUnfractionated Heparin.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e5.1 Introduction.\u003c\/p\u003e \u003cp\u003e5.2 Pharmacology.\u003c\/p\u003e \u003cp\u003e5.3 Clinical uses of UH.\u003c\/p\u003e \u003cp\u003e5.4 Clinical considerations.\u003c\/p\u003e \u003cp\u003e5.5 Conclusions.\u003c\/p\u003e \u003cp\u003eChapter 6. \u003cb\u003eLow-Molecular-Weight Heparins.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introduction.\u003c\/p\u003e \u003cp\u003e6.2 Comparisons between UH and LMWH.\u003c\/p\u003e \u003cp\u003e6.3 Clinical uses of LMWH.\u003c\/p\u003e \u003cp\u003e6.4 Conclusions.\u003c\/p\u003e \u003cp\u003eChapter 7 \u003cb\u003eDirect Thrombin Inhibitors.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e7.1 Introduction.\u003c\/p\u003e \u003cp\u003e7.2 Overview of DTIs.\u003c\/p\u003e \u003cp\u003e7.3 Clinical uses of DTIs.\u003c\/p\u003e \u003cp\u003e7.4 Summary.\u003c\/p\u003e \u003cp\u003eChapter 8. \u003cb\u003eFibrinolytic agents.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e8.1 Introduction.\u003c\/p\u003e \u003cp\u003e8.2 Fibrinolytic agents for STEMI.\u003c\/p\u003e \u003cp\u003e8.3 Fibrinolytics for VTE.\u003c\/p\u003e \u003cp\u003e8.4 Conclusions.\u003c\/p\u003e \u003cp\u003eChapter 9. \u003cb\u003eAcute ST-Segment-Elevation Myocardial Infarction.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e9.1 Introduction.\u003c\/p\u003e \u003cp\u003e9.2 Definitive therapy.\u003c\/p\u003e \u003cp\u003e9.3 Adjunctive therapy.\u003c\/p\u003e \u003cp\u003e9.4 Recommendations.\u003c\/p\u003e \u003cp\u003e9.5 Conclusions.\u003c\/p\u003e \u003cp\u003eChapter 10. \u003cb\u003eAcute Coronary Syndromes: Unstable Angina \/Non-ST-Segment-Elevation Myocardial Infarction (NSTE ACS).\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introduction.\u003c\/p\u003e \u003cp\u003e10.2 Antithrombotic approach to patients with ACS\/NSTEMI.\u003c\/p\u003e \u003cp\u003e10.3 Early invasive versus early conservative strategies.\u003c\/p\u003e \u003cp\u003e10.4 Recommendations.\u003c\/p\u003e \u003cp\u003e10.5 Conclusions.\u003c\/p\u003e \u003cp\u003eChapter 11 \u003cb\u003eAnticoagulation Strategies for Patients Undergoing Percutaneous Coronary Intervention.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e11.1 Introduction.\u003c\/p\u003e \u003cp\u003e11.2 Antiplatelet therapy.\u003c\/p\u003e \u003cp\u003e11.3 Antithrombotic therapy.\u003c\/p\u003e \u003cp\u003e11.4 Special populations.\u003c\/p\u003e \u003cp\u003e11.5 Recommendations.\u003c\/p\u003e \u003cp\u003e11.6 Conclusions.\u003c\/p\u003e \u003cp\u003eChapter 12 \u003cb\u003eVenous Thromboembolic Disease.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e12.1 Introduction.\u003c\/p\u003e \u003cp\u003e12.2 Risk of VTE.\u003c\/p\u003e \u003cp\u003e12.3 Prevention of VTE.\u003c\/p\u003e \u003cp\u003e12.4 Treatment of VTE.\u003c\/p\u003e \u003cp\u003e12.5 Conclusions.\u003c\/p\u003e \u003cp\u003eChapter 13. \u003cb\u003eHeparin-Induced Thrombocytopenia.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction.\u003c\/p\u003e \u003cp\u003e13.2 Incidence.\u003c\/p\u003e \u003cp\u003e13.3 Pathogenesis.\u003c\/p\u003e \u003cp\u003e13.4 Clinical manifestations.\u003c\/p\u003e \u003cp\u003e13.5 Diagnosis.\u003c\/p\u003e \u003cp\u003e13.6 Prevention.\u003c\/p\u003e \u003cp\u003e13.7 Treatment.\u003c\/p\u003e \u003cp\u003e13.8 Conclusions.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIndex.\u003c\/b\u003e\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49402314817879,"sku":"9780470319383","price":125.06,"currency_code":"GBP","in_stock":false}],"url":"https:\/\/bookcurl.com\/products\/management-strategies-in-antithrombotic-therapy-9780470319383","provider":"Book Curl","version":"1.0","type":"link"}